Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients

Abstract

There is controversy regarding the prognostic value of cathepsin-D in primary breast cancer. An increased level of cathepsin-D in tumour extracts has been found to be associated with a poor relapse-free and overall survival. Studies performed with immunohistochemistry or Western blotting have produced diverse results. We have analysed 2810 cytosolic extracts obtained from human primary breast tumours for cathepsin-D expression, and have correlated their levels with prognosis. The median follow-up of the patients still alive was 88 months. Patients with high cathepsin-D levels had a significantly worse relapse-free and overall survival, also in multivariate analysis (P < 0.0001). Adjuvant therapy which was associated with an improved prognosis in node-positive patients in univariate analysis, also significantly added to the multivariate models for relapse-free and overall survival. There were no statistically significant interactions between the levels of cathepsin-D and any of the classical prognostic factors in analysis for relapse-free survival, suggesting that the prognostic value of cathepsin-D is not different in the various subgroups of patients. Indeed, multivariate analyses in subgroups of node-negative and -positive patients, pre- and post-menopausal patients, and their combinations, showed that tumours with high cathepsin-D values had a significantly poor relapse-free survival, with relative hazard rates ranging from 1.3 to 1.5, compared with tumours with low cathepsin-D levels. The results presented here on 2810 patients confirm that high cytosolic cathepsin-D values are associated with poor prognosis in human primary breast cancer.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Briozzo P., Badet J., Capony F., Pieri I., Montcourrier P., Barritault D., Rochefort H. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res. 1991;194(2):252-259.

   Not in our library10.1016/0014-4827(91)90362-x

2. 2.

   Briozzo P., Morisset M., Capony F., Rougeot C., Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res. 1988;48(13):3688-3692.

   Not in our library

3. 3.

   Cardiff R. D. Cathepsin D and breast cancer: useful? Hum Pathol. 1994;25(9):847-848.

   Not in our library10.1016/0046-8177(94)90001-9

4. 4.

   Conover C. A., De Leon D. D. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem. 1994;269(10):7076-7080.

   Not in our library

5. 5.

   Domagala W., Striker G., Szadowska A., Dukowicz A., Weber K., Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol. 1992;141(5):1003-1012.

   Not in our library

6. 6.

   Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988;62(3):531-533.

   Not in our library10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b

7. 7.

   Emmert-Buck M. R. Cathepsin D and prognosis in breast cancer: one piece of a larger puzzle? Hum Pathol. 1996;27(9):869-871.

   Not in our library10.1016/s0046-8177(96)90211-7

8. 8.

   Ferrandina G., Scambia G., Bardelli F., Benedetti Panici P., Mancuso S., Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer. 1997;76(5):661-666.

   Not in our library10.1038/bjc.1997.442

9. 9.

   Foekens J. A., Portengen H., van Putten W. L., Peters H. A., Krijnen H. L., Alexieva-Figusch J., Klijn J. G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989;49(21):5823-5828.

   Not in our library

10. 10.

    Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Kramer M. D., Jänicke F., Klijn J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994;12(8):1648-1658.

    Not in our library10.1200/jco.1994.12.8.1648

11. 11.

    Foekens J. A., van Putten W. L., Portengen H., de Koning H. Y., Thirion B., Alexieva-Figusch J., Klijn J. G. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol. 1993;11(5):899-908.

    Not in our library10.1200/jco.1993.11.5.899

12. 12.

    Garcia M., Derocq D., Pujol P., Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene. 1990;5(12):1809-1814.

    Not in our library

13. 13.

    Henry J. A., McCarthy A. L., Angus B., Westley B. R., May F. E., Nicholson S., Cairns J., Harris A. L., Horne C. H. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990;65(2):265-271.

    Not in our library10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1

14. 14.

    Isola J., Weitz S., Visakorpi T., Holli K., Shea R., Khabbaz N., Kallioniemi O. P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol. 1993;11(1):36-43.

    Not in our library10.1200/jco.1993.11.1.36

15. 15.

    Joensuu H., Toikkanen S., Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer. 1995;71(1):155-159.

    Not in our library10.1038/bjc.1995.32

16. 16.

    Kute T. E., Shao Z. M., Sugg N. K., Long R. T., Russell G. B., Case L. D. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res. 1992;52(19):5198-5203.

    Not in our library

17. 17.

    Liaudet E., Derocq D., Rochefort H., Garcia M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ. 1995;6(9):1045-1052.

    Not in our library

18. 18.

    Nadji M., Fresno M., Nassiri M., Conner G., Herrero A., Morales A. R. Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol. 1996;27(9):890-895.

    Not in our library10.1016/s0046-8177(96)90214-2

19. 19.

    O'Donoghue A. E., Poller D. N., Bell J. A., Galea M. H., Elston C. W., Blamey R. W., Ellis I. O. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat. 1995;33(2):137-145.

    Not in our library10.1007/bf00682721

20. 20.

    Ravdin P. M. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat. 1993;24(3):219-226.

    Not in our library10.1007/bf01833262

21. 21.

    Ravdin P. M., Tandon A. K., Allred D. C., Clark G. M., Fuqua S. A., Hilsenbeck S. H., Chamness G. C., Osborne C. K. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994;12(3):467-474.

    Not in our library10.1200/jco.1994.12.3.467

22. 22.

    Razumović J. J., Stojković R. R., Petrovecki M., Gamulin S. Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat. 1997;43(2):117-122.

    Not in our library10.1023/a:1005789606641

23. 23.

    Remmele W., Sauer-Manthey J. Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1993;422(6):467-473.

    Not in our library10.1007/bf01606455

24. 24.

    Rochefort H. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer. 1994;30A(10):1583-1586.

    Not in our library10.1016/0959-8049(94)00317-x

25. 25.

    Rochefort H. The prognostic value of cathepsin D in breast cancer. A long road to the clinic. Eur J Cancer. 1996;32A(1):7-8.

    Not in our library10.1016/0959-8049(95)00637-0

26. 26.

    Roger P., Montcourrier P., Maudelonde T., Brouillet J. P., Pages A., Laffargue F., Rochefort H. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol. 1994;25(9):863-871.

    Not in our library10.1016/0046-8177(94)90004-3

27. 27.

    Saftig P., Hetman M., Schmahl W., Weber K., Heine L., Mossmann H., Köster A., Hess B., Evers M., von Figura K. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995;14(15):3599-3608.

    Not in our library10.1002/j.1460-2075.1995.tb00029.x

28. 28.

    Spyratos F., Maudelonde T., Brouillet J. P., Brunet M., Defrenne A., Andrieu C., Hacene K., Desplaces A., Rouëssé J., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989;2(8672):1115-1118.

    Not in our library10.1016/s0140-6736(89)91487-6

29. 29.

    Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990;322(5):297-302.

    Not in our library10.1056/nejm199002013220504

30. 30.

    Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989;49(21):6008-6014.

    Not in our library

31. 31.

    Têtu B., Brisson J., Côté C., Brisson S., Potvin D., Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 1993;55(3):429-435.

    Not in our library10.1002/ijc.2910550318

32. 32.

    Vignon F., Capony F., Chambon M., Freiss G., Garcia M., Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology. 1986;118(4):1537-1545.

    Not in our library10.1210/endo-118-4-1537

33. 33.

    Westley B. R., May F. E. Cathepsin D and breast cancer. Eur J Cancer. 1996;32A(1):15-24.

    Not in our library10.1016/0959-8049(95)00530-7

34. 34.

    Westley B., Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 1980;20(2):353-362.

    Not in our library10.1016/0092-8674(80)90621-2

35. 35.

    Westley B., Rochefort H. Estradiol induced proteins in the MCF7 human breast cancer cell line. Biochem Biophys Res Commun. 1979;90(2):410-416.

    Not in our library10.1016/0006-291x(79)91250-6

Cited by papers we hold 3

• Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis · 2017
  No notice
• Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration · 2012
  No notice
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.